Ironwood Pharmaceuticals saw the highest growth of 2.99% in patent filings and 0.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and grants by 0.49%. GlobalData’s DataBook provides a comprehensive analysis of Ironwood Pharmaceuticals’s patent filings and grants. Buy the databook here.
Ironwood Pharmaceuticals has been focused on protecting inventions in Australia(AU) with three publications in Q2 2024
The Australia(AU) Patent Office dominates the patent filings with nearly 43% of filings. The Australia(AU), United States(US), China(CN), and France(FR) patent Office are among the top ten patent offices where Ironwood Pharmaceuticals is filings its patents. Among the top granted patent authorities, Ironwood Pharmaceuticals has 50% of its grants in France(FR) and 50% in Croatia(HR).
Roche could be the strongest competitor for Ironwood Pharmaceuticals
Patents related to rare diseases and addiction lead Ironwood Pharmaceuticals's portfolio
Ironwood Pharmaceuticals has the highest number of patents in rare diseases followed by, addiction. For rare diseases, nearly 100% of patents were filed and 67% of patents were granted in Q2 2024.
Gastrointestinal related patents lead Ironwood Pharmaceuticals portfolio followed by gastroparesis, and ulcerative colitis
Ironwood Pharmaceuticals has highest number of patents in gastrointestinal followed by gastroparesis, ulcerative colitis, irritable bowel syndrome, and ileitis. For gastrointestinal, nearly 3% of patents were filed and 12% of patents were granted in Q2 2024.
For comprehensive analysis of Ironwood Pharmaceuticals's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.